Anti-CD3 immunotoxins exhibit considerable promise for the induction of transplantation tolerance in pre-clinical large animal models. Recently an anti-human anti-CD3ε single-chain immunotoxin based on truncated diphtheria toxin has been described that can be expressed in CHO cells that have been mutated to diphtheria toxin resistance. After the two toxin glycosylation sites were removed, the bioactivity of the expressed immunotoxin was nearly equal to that of the chemically conjugated immunotoxin. This immunotoxin, A-dmDT390-sFv, contains diphtheria toxin to residue 390 at the N-terminus followed by VL and VH domains of antibody UCHT1 linked by a (G 4 S) 3 spacer (sFv). Surprisingly, we now report that this immunotoxin is severely compromised in its binding affinity toward CD3 ⍣ cells as compared with the intact parental UCHT1 antibody, the UCHT1 Fab fragment or the engineered UCHT1 sFv domain alone. Binding was increased 7-fold by adding an additional identical sFv domain to the immunotoxin generating a divalent construct, A-dmDT390-bisFv (G 4 S). In vitro potency increased 10-fold over the chemically conjugated immunotoxin, UCHT1-CRM9 and the monovalent A-dmDT390-sFv. The in vivo potency of the genetically engineered immunotoxins was assayed in the transgenic heterozygote mouse, tgε 600, in which the T-cells express human CD3ε as well as murine CD3ε. Tcell depletion in the spleen and lymph node observed with the divalent construct was increased 9-and 34-fold, respectively, compared with the monovalent construct. The additional sFv domain appears partially to compensate for steric hindrance of immunotoxin binding due to the large N-terminal toxin domain.
Introduction
Immunotoxins are protein toxins that have undergone an alteration in cell specificity by replacement of the toxin receptor-binding domain with an alternative receptor-binding domain. As originally formulated, enzymatically active toxin A chain of diphtheria toxin was coupled to the alternate receptor binding domain of placental lactogen (Chang et al., 1977) . This and later work showed that the A chains of most toxins lacked efficient membrane protein translocation function and potent immunotoxins required a portion of the toxin B chain to aid the translocation process (Youle and Neville, 1982; Colombatti et al., 1986; Williams et al., 1987; Johnson et al., 1988; Siegall et al., 1989) . Structural and genetic studies identified the toxin domains and specific sequences involved primarily with binding as opposed to translocation (Choe et al., 1992) . The advent of recombinant methodology led to the construction of immunotoxin fusion proteins with domains that bound to cells using targeting molecules such as hormones, cytokines or recombinant antibody derivatives (Williams et al., 1987; Siegall et al., 1989; Kuan and Pastan, 1996) . However, immunotoxins that can kill 2-3 logs of target cells in vivo without high systemic toxicity have been elusive. Often, promising in vitro studies or in vivo xenograft models with cells exhibiting very high levels of receptor expression have failed to translate into good clinical therapies. Besides receptor number, other major variables affecting potency include downstream events in the intoxication pathway such as toxin processing reactions and receptor-mediated cell routing. Both of these vary with cell type and receptor type (Neville et al., 1989; Francisco et al., 1996) .
The T cell receptor protein CD3ε efficiently mediates the entry of diphtheria toxin-based immunotoxins (Neville et al., 1989) . In monkeys, reduction of 2-3 logs of lymph node T cells is achieved using a chemical conjugate of anti-rhesus CD3 antibody and CRM9, a diphtheria toxin binding-site mutant Hu et al., 1997) . Long-term tolerance to xenograft pancreatic islet transplants and renal allograft transplants have been described using this material Thomas et al., 2000) . We have described a monovalent recombinant form of this conjugate and its anti-human counterpart, DT390-sFv (UCHT1), that has reduced sensitivity to anti-DT neutralizing antibodies (Thompson et al., 1995; Ma et al., 1997) . The sFv moiety in this type of immunotoxin is restricted to the toxin C-terminus because the N-terminal toxin A chain can accept only a limited number of foreign residues before its enzymatic properties are compromised (Madshus et al., 1992) . This paper reports an optimized derivative DT390-sFv (UCHT1) immunotoxin. Our focus has been on improving the binding affinity of this recombinant immunotoxin. It appeared to us that this could most easily be accomplished by increasing the valency of the immunotoxin to reflect the divalency of the parental antibody. Our work has been patterned on previous efforts to form multivalent recombinant antibody derivatives (Holliger et al., 1993; Shu et al., 1993; Whitlow et al., 1993; Kipriyanov et al., 1994; Hu et al., 1996) , either through singlechain tandem sFv groups or through heavy chain disulfide bound dimeric structures, the so-called minibodies. We therefore made a systematic investigation of the binding of anti-CD3ε antibody fragments and recombinant derivatives to CD3ε expressing cells and the immunotoxins so derived. Linker size and placement were also investigated. In order to judge the in vivo potency of our optimized immunotoxin, we used a transgenic mouse that expresses human CD3ε (Wang et al., 1998) , thereby acquiring pre-clinical data but avoiding the use of large non-human primates. Our data suggest that this newly optimized molecule has valuable in vivo potential for the treatment of T cell tumors as well as induction of tolerance for transplantation.
Materials and methods

Monovalent immunotoxin construction
The construction of DT390-sFv has been described (Thompson et al., 1995) . This construct contains the first 390 amino acids of native DT, including the secretory signal peptide, upstream of the UCHT1 sFv [in the variable light (V L ) to variable heavy (V H ) configuration]. The V L -V H -linker is (G 4 S) 3 . A variant monovalent construct, M-DT389-sFv, was also produced (Hexham et al.) . This construct was expressed in Escherichia coli without a signal peptide and was refolded and purified from cytoplasmic inclusion bodies. This construct encoded an N-terminal methionine residue. In addition to having one less DT residue, this construct also contained a six-residue flexible linker (ASAGGS) between the DT moiety and the sFv moiety and the sequence of the V L -V H -linker was changed to (G 3 S) 4 , see Fig. 1 .
Bivalent single-chain immunotoxin construction
The generation of the bisFv construct was completed in two separate steps. In the first step, the 5Ј end of the UCHT1-sFv (V L ) was modified by polymerase chain reaction (PCR) to contain part of the linker sequence (the 3Ј end of the linker was added to the 5Ј end of the sFv). Additionally, the 3Ј end of the UCHT1-sFv (V H ) was modified to incorporate the 5Јend of the linker sequence. In the second step, the two sFv DNA sequences (V L -V H -linker and linker-V L -V H ) were verified to encode the appropriate amino acid sequences and subcloned together (V L -V H -linker-V L -V H ) using the unique BamHI restriction enzyme site. The bisFv sequence was then subcloned downstream of the DT390 sequence in pET15b to generate DT390-bisFv (G4S).
A similar scheme was used to create a bisFv construct using the CHB1 linker (Mallender and Voss, 1994) , between the two sFv domains. For the CHB1 linker, the two sFv DNA sequences (V L -V H -linker and linker-V L -V H ) were verified to encode the appropriate amino acid sequences and subcloned together (V L -V H -linker-V L -V H ) using the unique XhoI restriction enzyme site. The bisFv sequence was then subcloned downstream of the DT390 sequence in pET-15b to generate DT390-bisFv (CHB1).
Construction, expression and quantification of UCHT1 derivatives
The Fab fragment of UCHT1 was prepared by papain digestion using cross-linked agarose-papain (Pierce) following the manufacturer's directions. Contaminating Fc fragments and undigested UCHT1 were removed by absorption on to protein A Sepharose (Pierce). Fab was quantified by size-exclusion HPLC (GF-250 Zorbax) and UV absorption and integration using a UCHT1 standard and a correction for MW reduction.
The sFv and bisFv of UCHT1 were amplified by PCR. The template was DT390-bisFv (G4S) (see above) and the primers were chosen from the 5Ј end of V L and the 3Ј end of V H . The PCR products were checked by gel electrophoresis and the bands of sFv and bisFv of UCHT1 were cut out and extracted with a QIAquik Gel Extraction Kit (Qiagen, Chatsworth, CA). The extracted DNA was digested with NdeI and EcoRI and cloned into expression vector pET17b (Novagen) at NdeI and EcoRI sites. These were transformed into E.coli strain: BL21 (DE3)pLysS competent cells (Novagen). A single colony was cultured overnight. The overnight culture was re-cultured for 3-4 h with fresh medium to reach an OD 600 of 0.6, after which IPTG, 1 mM, was added to induce expression. The bacterial pellet was harvested by centrifugation. Inclusion bodies were prepared by the method of Buchner et al. (Buchner et al., 1992) and solubilization of inclusion bodies and refolding of the protein were performed according to Vallera et al. (Vallera et al., 1996) .
Minibody construction and expression
The [sFv(UCHT1)-H-γCH3-h]2 minibody was constructed by PCR overlap extension. This construct was patterned on the flex minibody described by Hu et al. (Hu et al., 1996) . The sFv (UCHT1) template was DT390-sFv (see above). In the minibody, the sFv region is followed by the hinge region of human IgG1 (residue 216 to residue 229). These residues were amplified from a plasmid containing human IgG1 heavy chain (supplied by Dr Syed Kashmiri, National Cancer Institute). In the hinge, residue C220 was changed to P (Shu et al., 1993) leaving C226 and C229 residues to form the interchain disulfide dimer. Between the hinge and γCH3, a flexible spacer, (G 3 S 2 ) 2 , was inserted following the construction of Hu et al . A histidine (h) tag of six residues was added at the C-terminus of γCH3 and a murine kappa signal peptide, MSVPTQVLGLLLLWLTDARC, was placed 5Ј to the sFv (Xiang, 1992) . This gene was cloned into pBacPAK8 (Clontech, Palo Alto, CA) and expressed in S9 cells at a level of 5 µg/ml as quantified by Coomassie Brilliant Blue staining using UCHT1 as a standard. Although the sFv of UCHT1 does not bind to Protein L Plus (Pierce) at pH 8.0 in PBS, it does bind in the presence of high salt. One volume of culture medium was mixed with 1.5 volumes of 2.5 M glycine-5 M NaCl, pH 9.0, and applied to a 1 ml column volume of Protein-L plus equilibrated with 1.5 M glycine-3 M NaCl, pH 9.0. The column was washed with two column volumes of application buffer and eluted with 4 ml of 0.25 M glycineHCl, pH 2.5. The divalent construct was quantified by Coomassie Brilliant Blue staining of SDS gels using a Fab (UCHT1) standard.
The [sFv(UCHT1)-µCH2-h]2 minibody construct was made by using PCR amplification, from previously cloned singlechain human IgM antibody construct (Ma et al., 1996) . The sFv(UCHT1)-µCH2-h construct was amplified by using 5Ј sFv and 3Ј CH2 primers. A six histidine residue tag was introduced to the 3Ј end of the CH2 domain. Following purification of the amplified sFv(UCHT1)-µCH2-h fragment by gel elution and digestion with EcoRI and NotI, it was inserted between the EcoRI and NotI sites of pET17b vector (Novagen). E.coli XL-1 Blue strain was used for all plasmid constructions. For expression in Pichia pastoris, pPICZα (Invitrogen, Carlsbad, CA) was used as the Pichia expression vector. The DNA sequence was confirmed by sequencing. KM71 was used as the host strain (Invitrogen). Maximum secretion of divalent anti-CD3 minibody could be obtained at 4 days after methanol induction in 1% yeast extract, 2% peptone, 100 mM potassium phosphate, pH 6.0, 1.34% yeast nitrogen base, 4ϫ10 -5 % biotin, 1% methanol plus 1% casamino acids to retard proteolysis. Western blots from non-reducing and reducing gels probed with polyclonal anti human IgM (Life Technologies, Bethesda, MD) confirmed the disulfide dimer, which accounted for 75% of the secreted material. Partial purification was achieved by absorbing contaminating proteins on DEAE Sepharose at pH 8.5 and applying the flow-through to Protein L agarose (Pierce) in the presence of 1.5 M glycine and 3 M NaCl, pH 8.9, and eluting with PBS diluted 1:3 in water. The divalent construct was quantified by Coomassie Brilliant Blue staining of SDS gels using a Fab (UCHT1) standard.
Construction, expression and quantification of HSAsFv(UCHT1)
The gene for the HSA-sFv(UCHT1) fusion construct codes from 5Ј to 3Ј the 609 residues of human serum albumin precursor variant A followed by a six-residue flexible linker (ASAGGS) and then the sFv moiety of sFv (UCHT1) used in DT389-sFv (see above). The fusion was performed by PCR overlap extension. This gene was cloned into the pHILD2 vector (Invitrogen) under the AOX1 promoter and expressed as a secreted form in Pichia pastoris GS115. HSAsFv(UCHT1) was purified from the supernatant by ammonium sulfate precipitation, followed by cation-exchange chromatography on a Bio-Rad S2 column at pH 6.0, where the protein was in the unbound fraction. HSA-sFv(UCHT1) was quantified by Lowry protein assay using an HSA standard.
Expression of other immunotoxins
The production of recombinant immunotoxins such as dmDT390-sFv(His6) from stably transfected DT resistant CHO cell lines by means of the pSRα-neo vector has been described (Liu et al., 2000) . The notation dm refers to the double mutation removing the potential N-glycosylation sites at positions 16-18 in the DT A chain and positions 235-237 in the DT B chain. The signal peptide used in CHO expression contained an additional terminal alanine to optimize the cleavage process at an Ala-Ala junction and therefore added an Ala residue to the DT N-terminus. This new construct is now called AdmDT390-sFv (after genetic removal of the C terminal His 6 tag). For CHO cell expression of the bivalent single-chain construct, DT390 was removed at the NcoI site from the DT390sFv plasmid for E.coli expression and replaced by spdmDT390 yielding on expression A-dmDT390-bisFv (G4S). The production of the disulfide-linked immunotoxins (A-DT390-sFv-H-γCH3-h)2 and (A-DT390-sFv-µCH2-h)2 was performed in CHO cells as described above, except that the glycosylation sites were not removed by mutation. These constructs were treated with N-glycosidase prior to toxicity assays under conditions that removed all detectable glycosylated forms (Liu et al., 2000) . M-DT389-sFv was expressed in E.coli and purified from cytoplasmic inclusion bodies as indicated above. Routine quantification was by Lowry protein assay calibrated by mass spectrometry.
Protein synthesis inhibition assay
Inhibition assays were performed as described previously (Neville et al., 1989) . Briefly, various concentrations of immunotoxin were incubated with Jurkat cells (1ϫ10 4 cells/ well of a 96-well plate) for 20 h. A 1 h pulse of [ 3 H]leucine (4.5 µC/ml) was given before cells were collected on filters In this work the heterozygote strain of the mouse, tgε600 ϩ/-, was used (F1 of tgε 600ϫC57BL/6J). These mice contain three copies of the complete human CD3ε gene under the transcriptional regulation of their endogenous promoters and enhancers (Wang et al., 1998) . A twice per day experimental dosing regimen was chosen because the monovalent immunotoxin was observed to have a short half-life in mice (Ͻ6 h). Accordingly, tgε600 ϩ/-were treated with immunotoxin twice daily for 4 days by tail vein administration using 0.1% murine serum albumin as a vehicle to prevent adsorption to plastic surfaces. Approximately 16 h after the final treatment, the lymph nodes and spleen were removed and single cell suspensions were prepared from individual mice. Total cells were counted by chamber counts. The percentage of CD3 positive cells was assessed by two-color FACS analysis using a FITC-conjugated anti-human CD3 antibody (UCHT1-FITC) to measure human CD3 expression, phycoerythrin (PE)-conjugated anti-mouse CD3 antibody (500A2-PE) to measure expression of mouse CD3 and the appropriately stained isotype controls. Viaprobe (Pharmingen, San Diego, CA) was used to gate on the live cells. Gates were set to count the fraction of double positive (DP) events (huCD3 ϩ muCD3 ϩ ) for the isotype controls in non-treated animals and the fraction of DP events in treated animals. The fraction of DP isotype controls was subtracted from the fraction of DP events in treated animals and the result, DPЈ, multiplied by the total cell count. This was subtracted from the DPЈ cells in control animals. The result was divided by the DPЈ cells in control animals to give the fractional depletion in DP cells at each immunotoxin concentration. (In non-treated animals 98-99% of the lymph node and spleen T cells were DP cells, the remaining being single positive muCD3 ϩ .) Mean fractional lymph node and spleen T cell depletion values were calculated for each immunotoxin concentration. The data were fitted by probit analysis using a log transformation of the concentration scale using SPSS software (SPSS, Chicago, IL). In probit transformation instead of regressing the actual proportion responding to the values of the stimuli, each of the observed proportions is replaced with the value of the standard normal curve below which the observed proportion of the area is found (Finney, 1978) . Data points for monovalent and divalent immunotoxin were fitted alone or together to yield parallel curves with one regression coefficient.
Results
Bivalent immunotoxin has increased binding
One potential way to increase the toxicity of the immunotoxin is to increase the binding of the molecule to the target, i.e. increase the affinity. To increase the binding characteristics of the immunotoxin, we prepared a variety of recombinant bivalent anti-CD3ε constructs and estimated their relative affinity compared to the parental antibody, UCHT1, and the monovalent Fab fragment of UCHT1. These studies were done to help us optimize the binding moiety of recombinant anti-CD3 immunotoxin. The mean relative binding values of the UCHT1 single-chain derivatives, lacking the DT moiety of the immunotoxin, were tested on Jurkat cells using the FACS-based assay (Table I ). Because plots of corrected mean channel fluorescence versus log concentration of competing UCHT1 or test ligands were not always parallel, comparisons were made at high, medium and low values of UCHT1-FITC displacement and the means and SDs were calculated. High SD values reflect relatively non-parallel curves.
The bivalent recombinant minibodies that were expressed in eukaryotic cells were secreted as disulfide dimers and had affinities equal to the parental divalent antibody. This was the case for the minibody that contained the hinge region and the γCH3 domain of human IgG1 as well as the minibody based on the human µCH2 domain. However, the monovalent sFv refolded from E.coli showed only half the affinity of the monovalent Fab fragment. The bisFv also refolded from E.coli was very avid and bound 1.5-fold better than the parental antibody. A significant finding was the fact that inserting a large protein domain at the N-terminus of the sFv domain, as in human serum albumin-sFv construct, decreased the binding by 100-fold compared with the parental antibody and decreased by 35-fold from the sFv alone. Indeed, addition of the DT moiety reduced the relative affinity of all immunotoxins tested (Table II) . The monovalent recombinant immunotoxins exhibit a large drop in affinity compared with their free sFv counterparts, similar to that seen by fusing human serum albumin on to the sFv N-terminus.
Bivalent single-chain immunotoxin has increased toxicity
To determine whether the observed increase in affinity of the bivalent constructs does increase the toxicity of immunotoxins, the DT390 moiety was added to each bivalent construct. The bivalent immunotoxins were tested for their toxicity on Jurkat cells in a 20 h protein synthesis inhibition assay (Table II) . The disulfide-linked dimer immunotoxins were relatively nontoxic. The monovalent immunotoxins had similar activity to UCHT1-CRM9 and an~3-fold increase in toxicity compared with the monovalent Fab-CRM9. There was no significant difference between the M-DT389-sFv that was produced in E.coli and refolded from inclusion bodies and the A-dmDT390-sFv construct that was secreted from CHO cells. However, it should be noted that the bacterial construct exhibited Ͻ3% nicking at the furin-sensitive bond between the A and B toxin chains, while the CHO material exhibited variable degrees of nicking from various preparations that ranged from 20 to 50%. Higher fractions of nicked material increased toxicity in Jurkat assays by a factor of 1.5 (data not shown). A bivalent construct utilizing a different linker sequence between the two sFv domains (Mallender and Voss, 1994) , DT390-bisFv (CHB1), demonstrated toxicity equivalent to DT390-sFv (data not Table II are illustrated, together with other constructs mentioned in the text. To determine the schematic UCHT1 derivatives used for the binding assay described in Table I , simply remove the DT390 moiety (A subfragment and B subfragment) from the representation above. The HSA-sFv (UCHT1) used in Table I is also shown since it has no DT constituent. The CHB1 linker described by Malleneder and Voss (Mallender and Voss, 1994) contains the amino acid sequence PGGNRGTTRPATSGSSPGPTNSHY in the indicated linker space. The (A-dmDT390-sFv-H-γCH3)2 and (A-dmDT390-sFv-µCH2)2 are secreted and purified as dimers which are bound by disulfide bridges (S-S) as indicated. The histidine tag (his) is shown. The double mutant (dm) amino acid changes are indicated (18S-A and 235N-A).
shown). On the other hand, the DT390-bisFv (G4S) construct showed increased toxicity compared with DT390-sFv. The in vitro translated DT390-sFv is~1.5 logs less toxic than UCHT1-CRM9 whereas purified DT390-sFv has similar toxicity to the chemical conjugate (Liu et al., 2000) . The relative toxicity between single-chain immunotoxins from the in vitro coupled transcription and translation has always predicted the relative toxicity of purified protein (data not shown).
Bivalent immunotoxin depletes human CD3 positive T-cells in tgε600 ϩ/-mice
To demonstrate the in vivo significance of the increased activity of the bivalent immunotoxin, we compared the ability of the bivalent and monovalent immunotoxins to deplete human CD3 positive T-cells in tgε600 ϩ/-mice. Increasing concentrations of immunotoxin were administered twice daily for 4 days. Spleens ( Figure 2A ) and lymph nodes ( Figure 2B ) from 3-9 animals were used to generate the means for each concentration. In both spleen and lymph node the mean depletion values from divalent immunotoxin are shifted to the left, indicating higher potency. The curves were fitted by probit analysis. The regression model is transformed Pi ϭ Aϩ BlogXi, where Pi is the observed proportion responding at dose logXi and B is the regression coefficient. The regression coefficient is related to the fractional depletion F by the empirical equation F ϭ X B /X B ϩ (IC 50 ) B . The divalent fitted curves are the solid lines. For the spleen fit, 54 cases were available for monovalent and 39 cases for divalent immunotoxin and the fits in Figure 2A were performed individually. The regression coefficients shown in Table III are nearly identical and the curves are nearly parallel. When both cases are fitted together (93 cases), the changes are minimal. The divalent immunotoxin is nine times more potent than the monovalent. The significance is high (Table III) . In the lymph node fit shown in Figure 2B , both monovalent and divalent were fitted together (89 cases). The curves are more shallow compared with the spleen curves. This result is influenced by the lowest concentration mean value of the divalent immunotoxin, which has a mean value of 0.4 compared with 0 in the spleen. In the lymph node the divalent immunotoxin appears 34-fold more potent than the monovalent immunotoxin based on the probit model.
Discussion
Previously, we reported the construction of a single-chain immunotoxin made with a truncated DT toxin moiety, DT390- Table III for probit-derived data. (B) As in (A) except done on lymph nodes. In this case all data points are fitted together generating a single regression coefficient for both immunotoxins. The listed dose is the total dose given over 4 days.
sFv, which was almost as toxic as a chemical conjugate made with the full length DT and intact antibody (Thompson et al., 1995; Liu et al., 2000) . A surprising result to emerge from this study was this monovalent immunotoxin, DT390-sFv, in addition to DT389-sFv, had a 22-fold loss of affinity relative to the parental sFv. This finding was unexpected because of the equal in vitro potencies of the monovalent immunotoxins relative the bivalent chemical conjugate. From these results, it can be concluded that the recombinant monovalent immuno-1040 toxin possesses highly efficient intoxication mechanisms downstream of the binding step that are able to compensate for poor binding. We reasoned that increasing the affinity of the monovalent recombinant immunotoxin by providing divalent binding would increase its potency. Our first attempts to increase the affinity involved the generation of divalent constructs including minibodies. Minibodies, first described by Hu et al. (Hu et al., 1996) , use a single interactive heavy chain domain to stabilize a disulfide dimerized sFv construct such as (sFv-H-γCH3-h)2. We also did this to a previously undescribed minibody utilizing the µCH2 domain to provide the stabilizing interaction and the interchain disulfide bond. These divalent constructs had identical affinity when compared with the native antibody, UCHT1. However, addition of DT390 moeities to the N-termini of the divalent minibodies drastically reduced their binding and failed to show an increase in binding over DT390sFv. In addition, their potency was almost non-existent. Because the addition of a single toxin moiety to the UCHT1 antibody decreased its affinity 3-fold, we suspected that the toxin moiety was providing steric inhibition to the Fv binding domain. If this was the case, positional effects might be important. In fact, addition of the human serum albumin sequence at the N-terminus of the sFv lowered the relative binding 35-fold. This suggested that the N-terminus of the sFv was sensitive to the presence of large foreign protein domains resulting in a reduction of sFv binding affinity. The mechanism could be steric inhibition or, alternatively, the additional moiety could alter overall protein folding, thereby affecting bioactivity (Martsev et al., 2000) .
A single-chain construct consisting of two tandem sFv domains provided a possible way to achieve bivalent binding and to minimize steric interactions at the C-terminal sFv. The divalent sFv, bisFv, had binding values slightly better than the native antibody. Addition of the DT390 moiety to the bisFv, A-dmDT390-bisFv (G4S), showed increased relative binding by 6-7-fold over the A-dmDT390-sFv. Moreover, the divalent construct had a 13-fold increase in in vitro toxicity compared with the monovalent immunotoxin and the chemical conjugate, UCHT1-CRM9. A bivalent construct utilizing an inter-sFv linker based on Mallender and Vos (Mallender and Voss, 1994) was only as toxic as the monovalent DT390-sFv (data not shown). This implies that the folding of the bivalent construct is an important variable in immunotoxin design. The DT390-bisFv (G4S) single-chain divalent immunotoxin represents a very significant increase in potency over previously described anti-CD3 immunotoxins and this increase in potency is due to an increase in binding to the CD3ε epitope.
The 10-fold enhanced potency of the divalent recombinant immunotoxin relative to the monovalent immunotoxin observed in Jurkat cells was also seen in spleen T cell depletion in the tgε600 ϩ/-mice that express human CD3ε. At the highest dose tested, 1026 pmol/kg, the fractional T cell depletion was 0.995 by the probit model. This dose was associated with significant immunosuppressive effects in allograft survival studies (Weetall et al., personal communication) . The enhanced potency of the divalent construct was 3-4-fold greater in the comparison of lymph nodes. This enhancement was within the range of the individual in vitro assays. Differences between lymph node and spleen data may reflect systematic experimental errors rather than real compartmental differences. However, one could expect a greater potency enhancement in vivo compared with in vitro owing to decreased renal clearance of the higher molecular weight divalent immunotoxin. Vallera et al. reported that a similar recombinant antimurine anti-CD3 monovalent immunotoxin utilizing DT390 induces renal toxicity (Vallera et al., 2000) , presumably by renal filtration and renal tubular reabsorption of this relatively low-MW immunotoxin. Renal toxicity was reduced by adding a C-terminal cysteine that generated a disulfide dimer immunotoxin and thus permitted higher in vivo dosing. However, this dimer did not exhibit any increase in in vitro potency. We suggest that this result was due to steric hindrance generated by the two DT390 moieties. The configuration of one DT390 moiety followed by a bisFv (G4S) moiety appears to attenuate the steric effect of a single N-terminal DT390 moiety on sFv binding and offers increased in vivo and in vitro potency over all pre-existing anti-CD3 immunotoxin constructs.
In summary, this report delineates the optimization of an anti-CD3 immunotoxin from the parental chemically conjugated immunotoxin through a monovalent recombinant immunotoxin to a divalent single-chain immunotoxin, A-dmDT390-bisFv (G4S). The parental chemically conjugated anti-human CD3 immunotoxin has a demonstrated in vivo activity against leukemic T cells, reducing these cells 3 logs at a tolerable dose in a xenograft model (Neville et al., 1992) . The chemically conjugated anti-rhesus analog can transiently deplete 2 logs of resting lymph node T cells in monkeys, a process that can induce long-term allograft transplantation tolerance (Huang et al., 2000; Thomas et al., 2000) . The availability of the optimized construct with a 13-fold increase in potency suggests that this reagent will be efficacious in vivo against human CD3 ϩ T cell leukemia/lymphoma. The fractional resting T cell depletion of 0.995 in the tgε600 ϩ/-mouse at 1026 pmol/ kg is noteworthy because this dose of DT389-IL-2, another truncated DT immunotoxin, is well tolerated clinically (Saleh et al., 1998) . This suggests that the optimization achieved with A-dmDT390-bisFv (G4S) may have resulted in a therapeutic window that will permit the use of T cell depletion tolerance protocols in human transplantation.
